Rettinger, Eva and Heckl, Dirk and Gibson, Brenda and Sauer, Martin and Turkiewicz, Dominik and Kleinschmidt, Katharina and Kalwak, Krzysztof and Reinhardt, Dirk and Locatelli, Franco and Klusmann, Jan-Henning (2025) The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia. LEUKEMIA, 39 (10). pp. 2313-2328. ISSN 0887-6924, 1476-5551
Full text not available from this repository. (Request a copy)Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly improved the outcome of children with high-risk (HR) acute myeloid leukemia (AML). Implementing allogeneic HSCT depends on numerous factors, including adverse cytogenetics, molecular abnormalities, poor response to first-line treatment, or relapsed or primary refractory disease. In HR AML, allogeneic HSCT is considered to be the consolidation strategy of choice in first complete remission (CR1) and offers the best chance of cure for patients with relapsed disease. Advances in donor/recipient typing, conditioning regimens, graft-versus-host-disease (GvHD) management, and supportive care have contributed to this improvement in overall-and transplant-outcome. This review will comprehensively discuss indications for HSCT and its modalities in pediatric AML by examining past, current, and future strategies for disease- and response-related stratification. We will examine the key importance of low/negative measurable residual disease (MRD) before transplantation and discuss conditioning regimens and graft variables, as well as novel approaches to harness the graft-versus-leukemia (GvL) effect, including targeted immunotherapy. The review will also address toxicities associated with HSCT, GvHD prophylaxis, and the management of treatment failure. Ultimately, this review seeks to inform clinical practice and highlights how improved outcomes have been achieved through the collective efforts of international study groups.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ACUTE MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; CORD BLOOD TRANSPLANTATION; HIGH-DOSE CYTARABINE; AIEOP-AML 2002/01; HIGH-RISK; UNRELATED DONOR; FLOW-CYTOMETRY |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Nov 2026 10:54 |
| Last Modified: | 19 Nov 2026 10:54 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67493 |
Actions (login required)
![]() |
View Item |

